BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

...Inc. include developing undisclosed PARG inhibitors for an undisclosed indication. Eli Lilly and Co. and Esperas Pharma Inc....
BioCentury | May 2, 2016
Clinical News

ESP-01: Phase Ib/IIa started

...or ovarian cancer. Esperas has worldwide rights to develop and commercialize ESP-01 from Eli Lilly. Esperas Pharma Inc....
BioCentury | Apr 20, 2015
Financial News

Esperas Pharma completes venture financing

Esperas Pharma Inc. , Montreal, Quebec Business: Cancer Date completed: 2015-04-13 Type: Venture financing Raised: $16.5 million Investors: TVM Life Science Ventures; Fonds de solidarite FTQ WIR Staff cancer...
Items per page:
1 - 3 of 3
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

...Inc. include developing undisclosed PARG inhibitors for an undisclosed indication. Eli Lilly and Co. and Esperas Pharma Inc....
BioCentury | May 2, 2016
Clinical News

ESP-01: Phase Ib/IIa started

...or ovarian cancer. Esperas has worldwide rights to develop and commercialize ESP-01 from Eli Lilly. Esperas Pharma Inc....
BioCentury | Apr 20, 2015
Financial News

Esperas Pharma completes venture financing

Esperas Pharma Inc. , Montreal, Quebec Business: Cancer Date completed: 2015-04-13 Type: Venture financing Raised: $16.5 million Investors: TVM Life Science Ventures; Fonds de solidarite FTQ WIR Staff cancer...
Items per page:
1 - 3 of 3